Indication
Melanoma stage III
26 clinical trials
38 products
7 drugs
Product
BNT111Clinical trial
Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV MelanomaStatus: Active (not recruiting), Estimated PCD: 2025-11-01
Product
CemiplimabProduct
SCIB1Clinical trial
A Phase 2, Multicentre, Open-Label Study of SCIB1 in Patients With Advanced Unresectable Melanoma Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study)Status: Recruiting, Estimated PCD: 2026-01-31
Product
L19IL2Product
L19TNFClinical trial
A Phase 2, Three-arm, Randomized Study of the Efficacy of Intratumorally Administered L19IL2 or L19TNF or L19IL2/L19TNF, All in Combination With Systemic Anti-PD1 Pembrolizumab, in Stage III and IV Unresectable Melanoma Patients With Resistance to or Progressing Upon Anti-PD1 Checkpoint Inhibitors and With Presence of Injectable MetastasesStatus: Active (not recruiting), Estimated PCD: 2028-07-01
Product
L19IL2/L19TNFProduct
EVX-02AClinical trial
A Phase 1/2, Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 After Complete Resection of Stage IIIB/IIIC/IIID or Stage IV Melanoma in Patients at High Risk for RecurrenceStatus: Terminated, Estimated PCD: 2023-02-28
Product
EVX-02Product
EVX-02BClinical trial
A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2026-07-01
Product
KB707Product
[203Pb]VMT01Product
[212Pb]VMT01Clinical trial
A Phase I/IIa, First-In-Human, Multi-Center Dose Escalation and Dose Expansion Study of [203/212Pb]VMT01 Receptor-Targeted, Image-Guided Alpha-Particle Therapy in Patients With Previously Treated Unresectable or Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2025-06-30
Product
SCIB1 DNA vaccineClinical trial
A Double-Blind Placebo-Controlled Comparative Randomized Clinical Study of the Efficacy and Safety of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 in Subjects With Metastatic Melanoma Concurrently Treated With PembrolizumabStatus: Recruiting, Estimated PCD: 2025-06-01
Product
SX-682Product
PembrolizumabProduct
BCD-217Product
BCD-100Product
PlaceboProduct
BempegaldesleukinClinical trial
A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)Status: Terminated, Estimated PCD: 2022-09-22
Product
anti-PD1Product
NivolumabClinical trial
A Randomized Study of the Efficacy and Safety of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) Versus Standard Adjuvant Therapy With Pembrolizumab in Patients With Resectable Stage III Skin Melanoma.Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
An Open Label, Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Checkpoint Inhibitor Treatment naïve Adults With Unresectable or Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2025-06-28
Product
EVX-01Clinical trial
Phase 1 Study to Evaluate the Safety and Efficacy of TILs Transduced With IL-7 (ADP-TILIL7) in Patients With Locally Advanced or Metastatic MelanomaStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Product
ADP-TILIL7Drug
cyclophosphamideDrug
fludarabineDrug
IL-2Clinical trial
A Phase II, Open Label, Single Arm Study of Neoadjuvant Pembrolizumab and Lenvatinib for Patients With Resectable Stage III MelanomaStatus: Active (not recruiting), Estimated PCD: 2023-01-31
Product
LenvatinibClinical trial
Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable DiseaseStatus: Active (not recruiting), Estimated PCD: 2023-04-09
Drug
T-VECClinical trial
Randomized Phase II Neoadjuvant Study of PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Resectable Stage III or Oligometastatic Stage IV Melanoma (Neo-MEL-T)Status: Recruiting, Estimated PCD: 2025-01-01
Product
DostarlimabProduct
Dostarlimab and TSR-022Clinical trial
A Phase-2 Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma - Definition of Two Additional Stratified Patient Cohorts of Regorafenib Plus BRAF-/MEK-inhibitors in Pretreated BRAF V600-mutant Melanoma PatientsStatus: Recruiting, Estimated PCD: 2024-12-01
Product
RegorafenibProduct
Triplet therapyClinical trial
A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced MelanomaStatus: Recruiting, Estimated PCD: 2026-01-01
Product
EncorafenibProduct
BinimetinibClinical trial
Adjuvant Nivolumab or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant NivolumabStatus: Recruiting, Estimated PCD: 2026-08-01
Drug
nivolumabProduct
IpilimumabClinical trial
Safe Stop IPI-NIVO Trial: Early Discontinuation of Nivolumab Upon Achieving a (Confirmed) Complete or Partial Response in Patients With Irresectable Stage III or Metastatic Melanoma Treated With First-line Ipilimumab-nivolumabStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase II Study of High Dose Bolus IL2 in Combination With Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 ImmunotherapyStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Biomarker Driven Patient Selection for Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma: A Pilot StudyStatus: Recruiting, Estimated PCD: 2027-03-01
Product
Nivolumab + RelatlimabDrug
LurbinectedinClinical trial
A Phase II Study of Binimetinib in Combination With Imatinib in Patients With Advanced KIT-Mutant MelanomaStatus: Recruiting, Estimated PCD: 2024-07-31
Product
ImatinibClinical trial
Phase II Study of Infliximab for the Treatment of Immune Checkpoint Inhibitor ColitisStatus: Recruiting, Estimated PCD: 2030-06-30
Product
InfliximabProduct
MethylprednisoloneDrug
R-CHOPClinical trial
Open Label Phase 2 Study Neo-Adjuvant BRAF/MEK Inhibition Followed by Surgery and Adjuvant BRAF/MEK Inhibition in In-transit Melanoma Metastases (NASAM)Status: Recruiting, Estimated PCD: 2026-01-01
Product
Encorafenib + BinimetinibClinical trial
The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma: A Prospective, Single-center, Phase 2 Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2024-12-31
Product
ToripalimabClinical trial
CD8+ Cell Imaging During Neoadjuvant ImmunoTherapy (The C-IT Neo Trial)Status: Recruiting, Estimated PCD: 2025-03-11
Product
Keytruda